Celgene Corp. Company Profile (NASDAQ:CELG)

About Celgene Corp.

Celgene Corp. logo

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. The Company's primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), POMALYST/IMNOVID (pomalidomide), VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (thalidomide), OTEZLA (apremilast) and ISTODAX (romidepsin). The Company's clinical trial activity includes trials across the disease areas of hematology, oncology, and inflammation and immunology.

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology
Sub-Industry: Biotechnology
Exchange: NASDAQ
Symbol: CELG
CUSIP: 15102010

Key Metrics:

Previous Close: $107.40
50 Day Moving Average: $109.2800
200 Day Moving Average: $105.2690
52-Week Range: $93.05 - $128.39
Trailing P/E Ratio: 44.6662
Foreward P/E Ratio: 16.46
P/E Growth: 0.8500
Market Cap: $81.91B
Outstanding Shares: 775,114,000
Beta: 1.31

Profitability:

Net Margins: 18.95%
Return on Equity: 67.06%
Return on Assets: 13.74%

Debt:

Debt-to-Equity Ratio: 2.58%
Current Ratio: 4.61%
Quick Ratio: 4.37%

Additional Links:

Companies Related to Celgene Corp.:

Consensus Ratings for Celgene Corp. (NASDAQ:CELG) (?)

Ratings Breakdown:	3 Hold Ratings, 23 Buy Ratings
Consensus Rating:	Buy (Score: 2.88)
Consensus Price Target:	$139.22 (31.55% upside)

Analysts' Ratings History for Celgene Corp. (NASDAQ:CELG)

Show:

Date	Firm	Action	Rating	Price Target
9/18/2016	Canaccord Genuity	Set Price Target	Buy	$156.00
9/16/2016	Bank of America Corp.	Reiterated Rating	Buy	$128.00
9/13/2016	Robert W. Baird	Reiterated Rating	Outperform	$162.00
9/13/2016	BMO Capital Markets	Reiterated Rating	Outperform	$141.00
9/13/2016	Jefferies Group	Reiterated Rating	Buy	$137.00
9/12/2016	Cowen and Company	Reiterated Rating	Outperform	$150.00
9/12/2016	Piper Jaffray Cos.	Reiterated Rating	Buy
9/12/2016	Leerink Swann	Reiterated Rating	Market Perform	$135.00
9/12/2016	Morgan Stanley	Reiterated Rating	Equal Weight	$120.00
9/7/2016	Argus	Reiterated Rating	Buy	$155.00
8/21/2016	BTIG Research	Reiterated Rating	Buy	$138.00
8/19/2016	JPMorgan Chase & Co.	Reiterated Rating	Overweight	$136.00
8/2/2016	Stifel Nicolaus	Reiterated Rating	Buy	$138.00
7/26/2016	RBC Capital Markets	Reiterated Rating	Buy
7/12/2016	Credit Suisse Group AG	Reiterated Rating	Outperform	$140.00
7/6/2016	JMP Securities	Reiterated Rating	Buy	$152.00
6/13/2016	Barclays PLC	Reiterated Rating	Positive
6/8/2016	Cantor Fitzgerald	Reiterated Rating	Buy
5/25/2016	William Blair	Reiterated Rating	Outperform
4/28/2016	Raymond James Financial Inc.	Reiterated Rating	Buy
4/28/2016	SunTrust Banks Inc.	Reiterated Rating	Buy	$145.00 -> $147.00
2/25/2016	Citigroup Inc.	Initiated Coverage	Buy	$130.00
2/22/2016	Goldman Sachs Group Inc.	Lower Price Target		$90.00 -> $83.00
1/29/2016	Royal Bank Of Canada	Lower Price Target	Outperform	$150.00 -> $135.00
1/22/2016	Wells Fargo & Co.	Reiterated Rating	Outperform
1/14/2016	Standpoint Research	Initiated Coverage	Buy	$130.00
12/18/2015	Atlantic Securities	Initiated Coverage	Neutral -> Neutral
7/25/2015	Nomura	Reiterated Rating	Buy	$165.00 -> $167.00
7/15/2015	Deutsche Bank AG	Boost Price Target	Buy	$160.00 -> $175.00
7/2/2015	Sanford C. Bernstein	Reiterated Rating	Buy	$154.00
1/30/2015	S&P Equity Research	Reiterated Rating	Strong-Buy

(Data available from 9/29/2014 forward)

Earnings History for Celgene Corp. (NASDAQ:CELG)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
11/3/2016
7/28/2016	Q216	$1.39	$1.44	$2.70 billion	$2.74 billion	View	Listen
4/28/2016	Q116	$1.29	$1.32	$2.59 billion	$2.51 billion	View	Listen
1/28/2016	Q415	$1.22	$1.18	$2.54 billion	$2.54 billion	View	Listen
11/5/2015	Q315	$1.22	$1.23	$2.40 billion	$2.33 billion	View	N/A
7/23/2015	Q215	$1.08	$1.23	$2.24 billion	$2.28 billion	View	Listen
4/30/2015	Q115	$1.06	$1.07	$2.11 billion	$2.08 billion	View	N/A
1/29/2015	Q414	$0.99	$1.01	$2.08 billion	$2.09 billion	View	N/A
10/23/2014	Q314	$0.95	$0.97	$1.96 billion	$1.96 billion	View	Listen
7/24/2014	Q214	$0.89	$0.90	$1.85 billion	$1.87 billion	View	N/A
4/24/2014	Q114	$1.65	$1.67	$1.77 billion	$1.71 billion	View	N/A
1/30/2014	Q413	$1.54	$1.51	$1.72 billion	$1.76 billion	View	Listen
10/24/2013	Q313	$1.54	$1.56	$1.64 billion	$1.67 billion	View	N/A
7/25/2013	Q2 2013	$1.44	$1.52	$1.54 billion	$1.56 billion	View	Listen
4/25/2013	Q1 2013	$1.35	$1.37	$1.47 billion	$1.43 billion	View	Listen
1/24/2013	Q4 2012	$1.31	$1.32	$1.45 billion	$1.42 billion	View	Listen
10/25/2012		$1.26	$1.29			View	N/A
7/26/2012		$1.19	$1.22			View	N/A
4/26/2012		$1.13	$1.08			View	N/A
1/26/2012		$1.06	$1.05			View	N/A
10/27/2011		$0.95	$1.02			View	N/A
7/28/2011		$0.85	$0.89			View	N/A
4/28/2011		$0.80	$0.83			View	N/A
1/27/2011		$0.73	$0.73			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Celgene Corp. (NASDAQ:CELG)

Current Year EPS Consensus Estimate: $5.11 EPS
Next Year EPS Consensus Estimate: $6.43 EPS

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2016	1	$1.09	$1.09	$1.09
Q2 2016	2	$1.25	$1.26	$1.26
Q3 2016	2	$1.28	$1.32	$1.30
Q4 2016	2	$1.35	$1.39	$1.37

(Data provided by Zacks Investment Research)

Dividend History for Celgene Corp. (NASDAQ:CELG)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Celgene Corp. (NASDAQ:CELG)

Insider Ownership Percentage: 0.97%
Institutional Ownership Percentage: 77.75%

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
9/23/2016	Richard W Barker	Director	Sell	20,000	$110.82	$2,216,400.00
9/15/2016	Gilla Kaplan	Director	Sell	9,710	$106.44	$1,033,532.40
8/23/2016	James J Loughlin	Director	Sell	27,500	$114.10	$3,137,750.00
8/22/2016	Michael D Casey	Director	Sell	43,134	$114.01	$4,917,707.34
7/28/2016	Robert J Hugin	Insider	Sell	100,000	$110.00	$11,000,000.00
6/20/2016	Robert J Hugin	Insider	Sell	75,000	$100.16	$7,512,000.00
4/4/2016	Gilla Kaplan	Director	Sell	15,967	$101.84	$1,626,079.28
3/3/2016	Michael W Bonney	Director	Buy	2,000	$103.01	$206,020.00
2/22/2016	James J Loughlin	Director	Sell	2,100	$104.12	$218,652.00
12/28/2015	Ernest Mario	Director	Sell	40,000	$119.36	$4,774,400.00
12/23/2015	Michael D Casey	Director	Sell	20,000	$122.11	$2,442,200.00
12/21/2015	Gilla Kaplan	Director	Sell	14,464	$110.62	$1,600,007.68
9/10/2015	Gilla Kaplan	Director	Sell	15,000	$122.45	$1,836,750.00
9/8/2015	Michael D. Casey	Director	Sell	15,000	$121.76	$1,826,400.00
7/13/2015	Thomas O Daniel	Insider	Sell	30,156	$120.78	$3,642,241.68
6/10/2015	Gilla Kaplan	Director	Sell	15,000	$111.74	$1,676,100.00
6/9/2015	Michael D Casey	Director	Sell	15,000	$111.18	$1,667,700.00
2/26/2015	Gilla Kaplan	Director	Sell	15,000	$122.89	$1,843,350.00
2/6/2015	Mark J Alles	Insider	Sell	117,099	$120.68	$14,131,507.32
1/15/2015	Lawrence V Stein	Insider	Sell	26,666	$120.01	$3,200,186.66
1/2/2015	Gilla Kaplan	Director	Sell	45,536	$113.47	$5,166,969.92
12/8/2014	Gilla Kaplan	Director	Sell	15,000	$118.20	$1,773,000.00
11/3/2014	Robert J Hugin	Insider	Sell	158,000	$106.68	$16,855,440.00
10/27/2014	Ernest Mario	Director	Sell	100,000	$102.85	$10,285,000.00
10/24/2014	Michael D Casey	Director	Sell	15,000	$102.94	$1,544,100.00
9/8/2014	Gilla Kaplan	Director	Sell	30,000	$93.73	$2,811,900.00
8/4/2014	Perry A Karsen	Insider	Sell	39,104	$87.55	$3,423,555.20
7/25/2014	Richard W Barker	Director	Sell	17,600	$87.03	$1,531,728.00
5/1/2014	Perry Karsen	Insider	Sell	11,922	$146.78	$1,749,911.16
3/4/2014	Michael Casey	Director	Sell	12,770	$162.33	$2,072,954.10
2/5/2014	Ernest Mario	Director	Sell	13,500	$151.87	$2,050,245.00
12/23/2013	Lawrence Stein	Insider	Sell	12,062	$168.19	$2,028,707.78
10/25/2013	Carrie Smith Cox	Director	Sell	18,750	$157.67	$2,956,312.50
9/4/2013	Gilla Kaplan	Director	Sell	15,000	$143.92	$2,158,800.00
8/28/2013	Thomas Daniel	Insider	Sell	32,263	$137.06	$4,421,966.78
8/2/2013	Perry A Karsen	Insider	Sell	93,008	$146.50	$13,625,672.00
5/30/2013	Robert J Hugin	Insider	Sell	68,087	$123.58	$8,414,191.46
5/29/2013	Ernest Mario	Director	Buy	1,000	$123.72	$123,720.00
5/28/2013	Thomas O Daniel	Insider	Sell	32,959	$124.91	$4,116,908.69

(Data available from 1/1/2013 forward)

Latest Headlines for Celgene Corp. (NASDAQ:CELG)

Date	Headline
	Biotech Stocks Worth a Closer Look: Celgene Corporation (NASDAQ:CELG), Sarepta Therapeutics, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:CELG) voiceregistrar.com - September 28 at 3:59 PM
	Will Celgene Depose Biogen to Become Top Dog In Multiple Sclerosis? (NASDAQ:CELG) www.fool.com - September 28 at 11:43 AM
	Celgene (CELG) Announces Long-Term Safety Findings for OTEZLA in Psoriasis and Psoriatic Arthritis (NASDAQ:CELG) www.streetinsider.com - September 28 at 8:55 AM
	Celgene Presents OTEZLA Long-Term Safety Data In Psoriasis,Psoriatic Arthritis (NASDAQ:CELG) www.rttnews.com - September 28 at 8:55 AM
	Julian Robertson: Biotech Stocks Are Cheap (NASDAQ:CELG) finance.yahoo.com - September 28 at 8:55 AM
	Oral OTEZLA® (apremilast) Long-Term Safety Data Presented at EADV Congress in Both Psoriasis and Psoriatic Arthritis (NASDAQ:CELG) finance.yahoo.com - September 28 at 8:55 AM
	3:19 am Celgene presents long-term safety data for ESTEEM 1 and 2 and PALACE 1-3 trials showed no increase in incidence of adverse events, no new safety signals and improved tolerability (NASDAQ:CELG) finance.yahoo.com - September 28 at 8:55 AM
	Top Gainers of the Day: Celgene Corporation (NASDAQ:CELG) from Biotechnology (NASDAQ:CELG) twincountynews.com - September 27 at 4:05 PM
	Celgene Corp. – Value Analysis (NASDAQ:CELG) : September 27, 2016 (NASDAQ:CELG) www.capitalcube.com - September 27 at 4:05 PM
	Amgen: The Blame Game (NASDAQ:CELG) blogs.barrons.com - September 27 at 4:05 PM
	Biotech Stocks To Put On Your Watch List: Celgene Corporation (NASDAQ:CELG), Tesaro, Inc. (NASDAQ:TSRO) - The Voice Registrar (NASDAQ:CELG) voiceregistrar.com - September 26 at 4:24 PM
	Ownership Change: Edgewood Management LLC Upped Holding in Celgene Corp (CELG) by $180.99 Million - Chester News (NASDAQ:CELG) www.chesterindependent.com - September 26 at 8:53 AM
	S&P 500 Stocks to Buy and Hold for the Next 10 Years (NASDAQ:CELG) portal.kiplinger.com - September 26 at 8:53 AM
	Biotechnology: Celgene Corporation (NASDAQ:CELG) Position of the day (NASDAQ:CELG) twincountynews.com - September 24 at 4:00 PM
	Stock in Limelight: Duke Realty Corporation (NYSE:DRE), Celgene Corporation (NASDAQ:CELG) - Newburgh Press (NASDAQ:CELG) newburghpress.com - September 23 at 3:34 PM
	Mike Khouw Sees Unusual Options Activity In Celgene - Benzinga (NASDAQ:CELG) www.benzinga.com - September 23 at 3:34 PM
	The Factors behind Gilead’s Discounted Valuation (NASDAQ:CELG) marketrealist.com - September 23 at 3:34 PM
	Time To Put On The Watch List? - Celgene Corporation (NASDAQ:CELG), Biogen Inc. (NASDAQ:BIIB) - The Voice Registrar (NASDAQ:CELG) voiceregistrar.com - September 22 at 9:47 AM
	3 Health Stocks to Own for the Next 10 Years (NASDAQ:CELG) portal.kiplinger.com - September 22 at 9:47 AM
	Leading stocks in today’s market: Celgene Corporation (NASDAQ:CELG) (NASDAQ:CELG) twincountynews.com - September 21 at 4:48 PM
	The Most Exciting Drug in Celgene's Pipeline (NASDAQ:CELG) www.fool.com - September 21 at 4:39 PM
	Stock in the Traders Limelight- Celgene Corporation's (CELG) (NASDAQ:CELG) myhealthbowl.com - September 21 at 8:10 AM
	Celgene Corporation (NASDAQ:CELG) Analyst Estimates (NASDAQ:CELG) thelakeandeswave.com - September 21 at 8:10 AM
	Celgene Corporation (CELG) Shares are Up 3.9% (NASDAQ:CELG) magseriesusa.net - September 21 at 8:10 AM
	Celgene Corporation: CELG Stock Charts Are a Must-See (NASDAQ:CELG) www.profitconfidential.com - September 21 at 8:10 AM
	Orphan Drug Designation among Latest Happenings at Ionis (NASDAQ:CELG) marketrealist.com - September 21 at 8:10 AM
	Trade of the Day: Celgene Corporation (CELG) Looking Healthy Again (NASDAQ:CELG) investorplace.com - September 20 at 7:27 AM
	High Market Cap Stock of the Day – Celgene Corporation (NASDAQ:CELG) (NASDAQ:CELG) twincountynews.com - September 19 at 4:56 PM
	Volatile Movements: Fiat Chrysler Automobiles NV(NYSE:FCAU), Celgene Corporation (NASDAQ:CELG), Concordia ... - NYSE Journal (press release) (NASDAQ:CELG) stockznews.com - September 19 at 8:55 AM
	Celgene Displays Oral Ozanimod’s Efficacy and Safety from Phase 2 RADIANCE Clinical Trial for Relapsing Multiple Sclerosis (MS) (NASDAQ:CELG) www.msunites.com - September 19 at 8:54 AM
	RBC Says These 4 Top Biotechs Could Have Big Upside Potential (NASDAQ:CELG) 247wallst.com - September 19 at 8:54 AM
	3 Top Stocks on Sale This Fall (NASDAQ:CELG) www.fool.com - September 19 at 8:54 AM
	Oral Ozanimod Efficacy and Safety Results at 2 Years from Phase 2 RADIANCE Trial of Patients with Relapsing ... - Business Wire (press release) (NASDAQ:CELG) www.businesswire.com - September 17 at 8:56 AM
	Oral Ozanimod Efficacy & Safety Results at 2 Years from Phase 2 RADIANCE Trial of Patients with Relapsing Multiple Sclerosis ... (NASDAQ:CELG) ih.advfn.com - September 16 at 4:04 PM
	Jefferies Expects Possible Deal For Celgene Corporation (CELG) With EngMab (NASDAQ:CELG) www.thecountrycaller.com - September 16 at 4:04 PM
	Company Update (NASDAQ:CELG): Celgene Reports Oral Ozanimod Efficacy and Safety Results at 2 Years from Phase 2 RADIANCE Trial at 32nd ECTRIMS (NASDAQ:CELG) www.smarteranalyst.com - September 16 at 4:04 PM
	Is Celgene Corporation (NASDAQ:CELG), a large market cap stock a smart buy? (NASDAQ:CELG) twincountynews.com - September 16 at 4:04 PM
	BRIEF-Celgene Corp- releases data on Phase 2 RADIANCE trial (NASDAQ:CELG) www.reuters.com - September 16 at 4:04 PM
	Stock's Report of the Thursday - Celgene Corporation's (CELG) - Hot Stocks Point (NASDAQ:CELG) www.hotstockspoint.com - September 16 at 4:04 PM
	BRIEF-Celgene Corp- releases data on Phase 2 RADIANCE trial - Reuters (NASDAQ:CELG) in.reuters.com - September 16 at 4:04 PM
	Celgene Outspends Big Pharmas in Deals (CELG) - Investopedia (NASDAQ:CELG) www.investopedia.com - September 15 at 9:36 PM
	Celgene's Big Bet May Pay Off (CELG) \| Investopedia - Investopedia (NASDAQ:CELG) www.investopedia.com - September 15 at 4:31 PM
	Celgene’s Big Bet May Pay Off (CELG) (NASDAQ:CELG) www.investopedia.com - September 15 at 4:31 PM
	Celgene Outspends Big Pharmas in Deals (CELG) (NASDAQ:CELG) www.investopedia.com - September 15 at 4:31 PM
	Hot Biotech Stocks Recap: Clovis Oncology, Inc. (NASDAQ:CLVS), Celgene Corporation (NASDAQ:CELG) - The Voice Registrar (NASDAQ:CELG) voiceregistrar.com - September 15 at 11:29 AM
	Analysts Valuations For Two Stocks: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Celgene Corporation (NASDAQ ... - The Voice Registrar (NASDAQ:CELG) voiceregistrar.com - September 15 at 11:29 AM
	5 Reasons Celgene Is a Buy - Motley Fool (NASDAQ:CELG) www.fool.com - September 15 at 11:29 AM
	5 Reasons Celgene Is a Buy (NASDAQ:CELG) www.fool.com - September 15 at 11:22 AM
	Celgene Corporation (NASDAQ:CELG) Rating At 1.35 - Stocks Daily (NASDAQ:CELG) www.stocksdaily.net - September 14 at 9:24 PM
	Summit Company Sponsoring First Ever Psoriatic Arthritis Awareness Day (NASDAQ:CELG) patch.com - September 14 at 9:24 PM